Gravitate Health FHIR Implementation Guide
0.1.0 - CI Build
Gravitate Health FHIR Implementation Guide
0.1.0 - CI Build
Gravitate Health FHIR Implementation Guide, published by Gravitate Health Project. This guide is not an authorized publication; it is the continuous build for version 0.1.0 built by the FHIR (HL7® FHIR® Standard) CI Build. This version is based on the current content of https://github.com/joofio/test-epi-composition/ and changes regularly. See the Directory of published versions
{
"resourceType" : "Bundle",
"id" : "bundlepackageleaflet-en-c94566dbffd326c95bc4d8ce17a5489a",
"meta" : {
"profile" : [
🔗 "http://hl7.org/fhir/uv/emedicinal-product-info/StructureDefinition/Bundle-uv-epi"
]
},
"language" : "en",
"identifier" : {
"system" : "http://ema.europa.eu/identifier",
"value" : "None"
},
"type" : "document",
"timestamp" : "2023-06-27T10:09:22Z",
"entry" : [
{
"fullUrl" : "Composition/composition-en-c94566dbffd326c95bc4d8ce17a5489a",
"resource" : {
"resourceType" : "Composition",
"id" : "composition-en-c94566dbffd326c95bc4d8ce17a5489a",
"meta" : {
"profile" : [
🔗 "http://hl7.org/fhir/uv/emedicinal-product-info/StructureDefinition/Composition-uv-epi"
]
},
"language" : "en",
"text" : {
"status" : "generated",
"div" : "<div xmlns=\"http://www.w3.org/1999/xhtml\" xml:lang=\"en\" lang=\"en\"><a name=\"Composition_composition-en-c94566dbffd326c95bc4d8ce17a5489a\"> </a><p class=\"res-header-id\"><b>Generated Narrative: Composition composition-en-c94566dbffd326c95bc4d8ce17a5489a</b></p><a name=\"composition-en-c94566dbffd326c95bc4d8ce17a5489a\"> </a><a name=\"hccomposition-en-c94566dbffd326c95bc4d8ce17a5489a\"> </a><a name=\"composition-en-c94566dbffd326c95bc4d8ce17a5489a-en-US\"> </a><div style=\"display: inline-block; background-color: #d9e0e7; padding: 6px; margin: 4px; border: 1px solid #8da1b4; border-radius: 5px; line-height: 60%\"><p style=\"margin-bottom: 0px\">Language: en</p><p style=\"margin-bottom: 0px\">Profile: <a href=\"https://build.fhir.org/ig/HL7/emedicinal-product-info/StructureDefinition-Composition-uv-epi.html\">Composition (ePI)</a></p></div><p><b>identifier</b>: <code>http://ema.europa.eu/identifier</code>/EU/1/18/1337/001</p><p><b>status</b>: Final</p><p><b>type</b>: <span title=\"Codes:{https://spor.ema.europa.eu/rmswi/ 100000155538}\">Package Leaflet</span></p><p><b>category</b>: <span title=\"Codes:{http://hl7.eu/fhir/ig/gravitate-health/CodeSystem/epicategory-cs R}\">Raw</span></p><p><b>date</b>: 2022-02-16 13:28:17+0000</p><p><b>author</b>: <a href=\"Organization-mah-ema.html\">Organization ACME industry</a></p><p><b>title</b>: TEST PURPOSES ONLY - ghryvelin</p><h3>Attesters</h3><table class=\"grid\"><tr><td style=\"display: none\">-</td><td><b>Mode</b></td><td><b>Time</b></td></tr><tr><td style=\"display: none\">*</td><td><span title=\"Codes:{http://hl7.org/fhir/composition-attestation-mode official}\">Official</span></td><td>2022-02-16 13:28:17+0000</td></tr></table></div>"
},
"identifier" : [
{
"system" : "http://ema.europa.eu/identifier",
"value" : "EU/1/18/1337/001"
}
],
"status" : "final",
"type" : {
"coding" : [
{
"system" : "https://spor.ema.europa.eu/rmswi/",
"code" : "100000155538"
}
],
"text" : "Package Leaflet"
},
"category" : [
{
"coding" : [
{
"system" : "http://hl7.eu/fhir/ig/gravitate-health/CodeSystem/epicategory-cs",
"code" : "R",
"display" : "Raw"
}
]
}
],
"subject" : [
{
"reference" : "MedicinalProductDefinition/mpc94566dbffd326c95bc4d8ce17a5489a"
}
],
"date" : "2022-02-16T13:28:17Z",
"author" : [
{
🔗 "reference" : "Organization/mah-ema"
}
],
"title" : "TEST PURPOSES ONLY - ghryvelin",
"attester" : [
{
"mode" : {
"coding" : [
{
"system" : "http://hl7.org/fhir/composition-attestation-mode",
"code" : "official"
}
]
},
"time" : "2022-02-16T13:28:17Z"
}
],
"section" : [
{
"title" : "B. Package Leaflet",
"code" : {
"coding" : [
{
"system" : "https://spor.ema.europa.eu/rmswi/",
"code" : "100000155538"
}
],
"text" : "B. Package Leaflet"
},
"text" : {
"status" : "additional",
"div" : "<div xmlns=\"http://www.w3.org/1999/xhtml\">unavailable</div>"
},
"emptyReason" : {
"coding" : [
{
"system" : "http://terminology.hl7.org/CodeSystem/list-empty-reason",
"code" : "unavailable"
}
]
},
"section" : [
{
"title" : "Package leaflet: Information for the user",
"code" : {
"coding" : [
{
"system" : "https://spor.ema.europa.eu/rmswi/",
"code" : "100000155538"
}
],
"text" : "Package leaflet: Information for the user"
},
"text" : {
"status" : "additional",
"div" : "<div xmlns=\"http://www.w3.org/1999/xhtml\"></div>"
}
},
{
"title" : "What is in this leaflet",
"code" : {
"coding" : [
{
"system" : "https://spor.ema.europa.eu/rmswi/",
"code" : "100000155538"
}
],
"text" : "What is in this leaflet"
},
"text" : {
"status" : "additional",
"div" : "<div xmlns=\"http://www.w3.org/1999/xhtml\"><p>What is in this leaflet</p><ol type=\"1\"><li>What GHRYVELIN is and what it is used for</li><li>What you need to know before GHRYVELIN is given</li><li>How GHRYVELIN is given</li><li>Possible side effects</li><li>How GHRYVELIN is stored</li><li>Contents of the pack and other information</li></ol></div>"
}
},
{
"title" : "1. What ghryvelin is and what it is used for",
"code" : {
"coding" : [
{
"system" : "https://spor.ema.europa.eu/rmswi/",
"code" : "100000155538"
}
],
"text" : "1. What ghryvelin is and what it is used for"
},
"text" : {
"status" : "additional",
"div" : "<div xmlns=\"http://www.w3.org/1999/xhtml\"><p>The medicine contains an active substance called macimorelin. Macimorelin acts like a natural hormone and causes the pituitary gland to release growth hormone into the blood stream.</p><p>GHRYVELIN is used in adults to test the body s ability to produce growth hormone. It is used when your doctor thinks that you may not have enough growth hormone (adult growth hormone deficiency). This is not a treatment for patients who do not have enough growth hormone. It is a test that helps your doctor to diagnose this condition.</p></div>"
}
},
{
"title" : "2. What you need to know before you take ghryvelin",
"code" : {
"coding" : [
{
"system" : "https://spor.ema.europa.eu/rmswi/",
"code" : "100000155538"
}
],
"text" : "2. What you need to know before you take ghryvelin"
},
"text" : {
"status" : "additional",
"div" : "<div xmlns=\"http://www.w3.org/1999/xhtml\"><p>You must not be given GHRYVELIN</p><ul><li>if you are allergic to macimorelin or any of the other ingredients of this medicine (listed in section 6).</li></ul><p>If you are not sure, talk to your doctor or nurse before you are given GHRYVELIN.</p><p>Warnings and precautions To ensure that the test results are reliable, you need to follow the rules below:</p><ul><li>Fasting - you must not eat for at least 8 hours before the test, and during the test.</li><li>Physical exercise - avoid strenuous physical activity 24 hours before the test.</li><li>Drinking - up to 100 mL of still water is allowed each within 1 hour before as well as within 1 hour after macimorelin intake.</li></ul><p>Talk to your doctor or nurse if:</p><ul><li>you have recently been treated with growth hormone (somatotropin) or with medicines that affect the secretion of growth hormone by the pituitary gland. You need to stop such treatment at least 1 month before the test.</li><li>you have recently been treated for Cushing s disease (disorder which results in high levels of the hormone cortisol) or if you are receiving a high dose of hydrocortisone medicine, the test may lead to false positive test results.</li><li>your body is lacking any other hormone e.g. cortisol, thyroid or sex hormones, vasopressin (in diabetes insipidus), this should be adequately replaced before testing for growth hormone deficiency. Other hormone deficiencies if untreated could lead to inaccurate results in the growth hormone stimulation test.</li><li>you have heart disease or problems with your heart rhythm (including congenital or acquired long QT syndrome or a history of so called torsades de pointes tachycardias). GHRYVELIN can cause changes in the ECG (electrocardiogram) including QT prolongation that are associated with an increased risk for arrhythmias. If occurring, such changes would be timely limited and not last long.</li></ul><p>If any of the above applies to you, or if you are not sure, talk to your doctor or nurse before you are given this medicine.</p><p>GHRYVELIN is indicated as a single-dose diagnostic test. No information is available on the safety and effects of macimorelin during long-term use. Potentially re-test needed in early disease If the adult growth hormone deficiency just recently started and if it is due to an injury in a section of the brain called hypothalamus, then the test result could be negative although you have the disease. In such a situation, a repetition of the test may be required.</p><p>Children and adolescents GHRYVELIN must not be used in children and adolescents aged below 18 years, because the safety and effectiveness in these groups have not yet been established.</p><p>Other medicines and GHRYVELIN Tell your doctor if you are taking, have recently taken or might take any other medicines.</p><p>Tell your doctor if you are taking medicines that can alter your heart rhythm, such as:</p><ul><li>medicines to treat psychosis (such as chlorpromazine, haloperidol)</li><li>medicines to treat infections (antibiotics such as erythromycin, clarithromycin, moxifloxacin)</li><li>medicines to correct the heart rhythm (antiarrhythmic medicines such as amiodarone, procainamide, quinidine or sotalol)</li><li>any other medicines that can prolong the QT interval or inducing torsades de pointes</li></ul><p>Tell your doctor if you are taking medicines that could increase the breakdown of macimorelin such as specific medicines to treat:</p><ul><li>seizures/epilepsy (carbamazepine, esclicarbazepine, fosphenytoin, oxcarbazepine, phenobarbital, phenytoin, primidone)</li><li>sleep disorder (modafinil, pitolisant)</li><li>mild to moderate depressive episodes (St. John s wort (Hypericum perforatum))</li><li>cystic fibrosis (lumacaftor)</li><li>infections (antibiotics such as rifabutin, rifampicin)</li><li>HIV (efavirenz, nevirapine)</li><li>type 2 diabetes (pioglitazone)</li><li>cancer (dabrafenib, enzalutamide)</li></ul><p>Tell your doctor if you are taking medicines that may impact the accuracy of the diagnostic test. Avoid concomitant use with medicines:</p><ul><li>that could have a direct influence on growth hormone secretion by the pituitary gland: such as somatostatin, insulin, glucocorticoids, acetylsalicylic acid, indometacin</li><li>that could increase growth hormone levels: such as clonidine, levodopa, insulin</li><li>that could reduce the growth hormone response to macimorelin such as: atropine, propylthiouracil, growth hormone medicines</li></ul><p>Pregnancy and breast-feeding If you are pregnant or breast-feeding, think you may be pregnant or are planning to have a baby, ask your doctor or nurse for advice before this medicine is given to you. GHRYVELIN is not recommended during pregnancy. If you are a woman able to have children, you must use effective contraceptive methods to ensure you are not pregnant at the time of the test. If you are breast-feeding or intend to breast-feed, a risk to the suckling child cannot be excluded. Please ask your doctor whether to discontinue breast-feeding or to abstain from the macimorelin test.</p><p>Driving and using machines Dizziness can occur with GHRYVELIN. If this happens, do not drive or use machines.</p><p>GHRYVELIN contains lactose If you have been told by your doctor that you have an intolerance to some sugars, contact your doctor before taking this medicine.</p><p>GHRYVELIN contains sodium This medicine contains less than 1 mmol sodium (23 mg) per sachet, that is to say it is essentially sodium-free .</p></div>"
}
},
{
"title" : "3. How to take ghryvelin",
"code" : {
"coding" : [
{
"system" : "https://spor.ema.europa.eu/rmswi/",
"code" : "100000155538"
}
],
"text" : "3. How to take ghryvelin"
},
"text" : {
"status" : "additional",
"div" : "<div xmlns=\"http://www.w3.org/1999/xhtml\"><p>A healthcare professional must supervise the preparation and use of GHRYVELIN. Instructions are given at the end of this leaflet on how to prepare the test. The description in this leaflet is for your information on the testing procedure. You must be fasting for at least 8 hours before you are given GHRYVELIN. You may not perform strenuous physical exercises 24 hours before the test. You can drink up to 100 mL of still water within 1 hour before and within 1 hour after intake of GHRYVELIN.</p><p>Dose The recommended dose is 0.5 mg GHRYVELIN per kg body weight. This corresponds to a volume of 1 mL of the prepared suspension per kg body weight. You have to drink the complete test dose within 30 seconds. You will have three blood samples taken to measure growth hormone, one sample each at 45, 60 and 90 minutes after taking the test dose.</p><p>If you are given more GHRYVELIN than you should If you are given more GHRYVELIN than you should, tell your doctor or nurse. Possible side effects in cases of overdosing could include headache, nausea, vomiting and diarrhoea. In case you should have heart rhythm disturbances, an ECG monitoring will be performed.</p><p>If you have any further questions on the use of this medicine, ask your doctor or nurse.</p></div>"
}
},
{
"title" : "4. Possible side effects",
"code" : {
"coding" : [
{
"system" : "https://spor.ema.europa.eu/rmswi/",
"code" : "100000155538"
}
],
"text" : "4. Possible side effects"
},
"text" : {
"status" : "additional",
"div" : "<div xmlns=\"http://www.w3.org/1999/xhtml\"><p>Like all medicines, this medicine can cause side effects, although not everybody gets them.</p><p>Common side effects (may affect up to 1 in 10 people):</p><ul><li>a bitter or metallic taste (dysgeusia)</li><li>tiredness</li><li>headache</li><li>feeling sick (nausea)</li><li>dizziness</li><li>diarrhoea</li><li>feeling hot</li></ul><p>These side effects are mostly mild, do not last long, and usually go away quickly without treatment.</p><p>Uncommon side effects (may affect up to 1 in 100 people):</p><ul><li>abdominal pain</li><li>feeling cold</li><li>hunger</li><li>palpitations</li><li>lower than normal heart rate (sinus bradycardia)</li><li>sleepiness</li><li>thirst</li><li>tremor</li><li>vertigo</li></ul><p>Frequency not known (cannot be estimated from the available data):</p><ul><li>changes in the electrocardiogram (ECG) Reporting of side effects If you get any side effects, talk to your doctor or nurse. This includes any possible side effects not listed in this leaflet. You can also report side effects directly via the national reporting system listed in Appendix V. By reporting side effects, you can help provide more information on the safety of this medicine.</li></ul></div>"
}
},
{
"title" : "5. How to store ghryvelin",
"code" : {
"coding" : [
{
"system" : "https://spor.ema.europa.eu/rmswi/",
"code" : "100000155538"
}
],
"text" : "5. How to store ghryvelin"
},
"text" : {
"status" : "additional",
"div" : "<div xmlns=\"http://www.w3.org/1999/xhtml\"><p>Keep this medicine out of the sight and reach of children. Do not use this medicine after the expiry date which is stated on the outer carton and the sachet after EXP. The expiry date refers to the last day of that month. Store in the original package, in order to protect from light and moisture. Store in a refrigerator (2 C 8 C). Unopened sachet The shelf life of a sachet is 5 years. Reconstituted suspension The suspension must be taken within 30 minutes after preparation. Any remaining suspension must be discarded by your doctor or nurse according to local regulations.</p><p>Do not throw away any medicines via wastewater or household waste. These measures will help protect the environment.</p></div>"
}
},
{
"title" : "6. Contents of the pack and other information",
"code" : {
"coding" : [
{
"system" : "https://spor.ema.europa.eu/rmswi/",
"code" : "100000155538"
}
],
"text" : "6. Contents of the pack and other information"
},
"text" : {
"status" : "additional",
"div" : "<div xmlns=\"http://www.w3.org/1999/xhtml\"><p>What GHRYVELIN contains</p><ul><li>The active substance is macimorelin. Each sachet contains 60 mg macimorelin (as acetate). 1 mL of the reconstituted suspension contains 500 micrograms macimorelin.</li><li>The other ingredients are: lactose monohydrate (see section 2 under GHRYVELIN contains lactose ), colloidal anhydrous silica, crospovidone type A, saccharin sodium dihydrate and sodium stearyl fumarate (see section 2 under GHRYVELIN contains sodium ).</li></ul><p>What GHRYVELIN looks like and contents of the pack GHRYVELIN is presented as white to off-white granules for oral suspension. Each sachet contains 1,817 mg granules. Each cardboard box contains 1 sachet.</p><p>Marketing Authorisation Holder Atnahs Pharma Netherlands B. V. Copenhagen Towers restads Boulevard 108, 5.tv DK-2300 K benhavn S Denmark</p><p>Manufacturer Aeterna Zentaris GmbH Weism llerstrasse D-60314 Frankfurt am Main Germany</p><p>This leaflet was last revised in Other sources of information Detailed information on this medicine is available on the European Medicines Agency web site: <a href=\"http://www.ema.europa.eu\">http://www.ema.europa.eu</a></p></div>"
}
}
]
}
]
}
},
{
"fullUrl" : "MedicinalProductDefinition/mpc94566dbffd326c95bc4d8ce17a5489a",
"resource" : {
"resourceType" : "MedicinalProductDefinition",
"id" : "mpc94566dbffd326c95bc4d8ce17a5489a",
"meta" : {
"profile" : [
🔗 "http://hl7.org/fhir/uv/emedicinal-product-info/StructureDefinition/MedicinalProductDefinition-uv-epi"
]
},
"text" : {
"status" : "generated",
"div" : "<div xmlns=\"http://www.w3.org/1999/xhtml\"><a name=\"MedicinalProductDefinition_mpc94566dbffd326c95bc4d8ce17a5489a\"> </a><p class=\"res-header-id\"><b>Generated Narrative: MedicinalProductDefinition mpc94566dbffd326c95bc4d8ce17a5489a</b></p><a name=\"mpc94566dbffd326c95bc4d8ce17a5489a\"> </a><a name=\"hcmpc94566dbffd326c95bc4d8ce17a5489a\"> </a><a name=\"mpc94566dbffd326c95bc4d8ce17a5489a-en-US\"> </a><p><b>identifier</b>: <code>http://ema.europa.eu/identifier</code>/EU/1/18/1337/001</p><p><b>type</b>: <span title=\"Codes:{http://hl7.org/fhir/medicinal-product-type MedicinalProduct}\">Medicinal Product</span></p><p><b>domain</b>: <span title=\"Codes:{http://hl7.org/fhir/medicinal-product-domain Human}\">Human use</span></p><p><b>status</b>: <span title=\"Codes:{http://hl7.org/fhir/publication-status active}\">active</span></p><p><b>legalStatusOfSupply</b>: <span title=\"Codes:{https://spor.ema.europa.eu/rmswi 100000072084}\">Medicinal product subject to medical prescription</span></p><blockquote><p><b>name</b></p><p><b>productName</b>: GHRYVELIN 60 mg granules for oral suspension in sachet</p><p><b>type</b>: <span title=\"Codes:{https://spor.ema.europa.eu/lists/220000000000 220000000001}\">Full name</span></p><blockquote><p><b>part</b></p><p><b>part</b>: nan</p><p><b>type</b>: <span title=\"Codes:{https://spor.ema.europa.eu/lists/220000000000 220000000002}\">Invented name part</span></p></blockquote><blockquote><p><b>part</b></p><p><b>part</b>: nan</p><p><b>type</b>: <span title=\"Codes:{https://spor.ema.europa.eu/lists/220000000000 220000000003}\">Scientific name part</span></p></blockquote><blockquote><p><b>part</b></p><p><b>part</b>: nan</p><p><b>type</b>: <span title=\"Codes:{https://spor.ema.europa.eu/lists/220000000000 220000000004}\">Strength part</span></p></blockquote><blockquote><p><b>part</b></p><p><b>part</b>: nan</p><p><b>type</b>: <span title=\"Codes:{https://spor.ema.europa.eu/lists/220000000000 220000000005}\">Pharmaceutical dose form part</span></p></blockquote><h3>Usages</h3><table class=\"grid\"><tr><td style=\"display: none\">-</td><td><b>Country</b></td><td><b>Jurisdiction</b></td><td><b>Language</b></td></tr><tr><td style=\"display: none\">*</td><td><span title=\"Codes:{urn:iso:std:iso:3166 EU}\">EU</span></td><td><span title=\"Codes:{urn:iso:std:iso:3166 EU}\">EU</span></td><td><span title=\"Codes:{urn:ietf:bcp:47 en}\">en</span></td></tr></table></blockquote></div>"
},
"identifier" : [
{
"system" : "http://ema.europa.eu/identifier",
"value" : "EU/1/18/1337/001"
}
],
"type" : {
"coding" : [
{
"system" : "http://hl7.org/fhir/medicinal-product-type",
"code" : "MedicinalProduct",
"display" : "Medicinal Product"
}
]
},
"domain" : {
"coding" : [
{
"system" : "http://hl7.org/fhir/medicinal-product-domain",
"code" : "Human",
"display" : "Human use"
}
]
},
"status" : {
"coding" : [
{
"system" : "http://hl7.org/fhir/publication-status",
"code" : "active",
"display" : "active"
}
]
},
"legalStatusOfSupply" : {
"coding" : [
{
"system" : "https://spor.ema.europa.eu/rmswi",
"code" : "100000072084",
"display" : "Medicinal product subject to medical prescription"
}
]
},
"name" : [
{
"productName" : "GHRYVELIN 60 mg granules for oral suspension in sachet",
"type" : {
"coding" : [
{
"system" : "https://spor.ema.europa.eu/lists/220000000000",
"code" : "220000000001",
"display" : "Full name"
}
]
},
"part" : [
{
"part" : "nan",
"type" : {
"coding" : [
{
"system" : "https://spor.ema.europa.eu/lists/220000000000",
"code" : "220000000002",
"display" : "Invented name part"
}
]
}
},
{
"part" : "nan",
"type" : {
"coding" : [
{
"system" : "https://spor.ema.europa.eu/lists/220000000000",
"code" : "220000000003",
"display" : "Scientific name part"
}
]
}
},
{
"part" : "nan",
"type" : {
"coding" : [
{
"system" : "https://spor.ema.europa.eu/lists/220000000000",
"code" : "220000000004",
"display" : "Strength part"
}
]
}
},
{
"part" : "nan",
"type" : {
"coding" : [
{
"system" : "https://spor.ema.europa.eu/lists/220000000000",
"code" : "220000000005",
"display" : "Pharmaceutical dose form part"
}
]
}
}
],
"usage" : [
{
"country" : {
"coding" : [
{
"system" : "urn:iso:std:iso:3166",
"code" : "EU",
"display" : "EU"
}
]
},
"jurisdiction" : {
"coding" : [
{
"system" : "urn:iso:std:iso:3166",
"code" : "EU",
"display" : "EU"
}
]
},
"language" : {
"coding" : [
{
"system" : "urn:ietf:bcp:47",
"code" : "en",
"display" : "en"
}
]
}
}
]
}
]
}
}
]
}
IG © 2021+ Gravitate Health Project. Package hl7.eu.fhir.ghepi#0.1.0 based on FHIR 5.0.0. Generated 2024-10-14
Links: Table of Contents |
QA Report
The Gravitate Health project has received funding from the IMI 2 Joint Undertaking under grant agreement No 945334.
This joint undertaking receives support from the EU H2020 research and innovation programme and EFPIA.
